r PTN Stock Quote - Palatin Technologies, Inc. Stock Price Today
TONIGHT! Join in as Kyle Dennis, 27 year-old,
self-made millionaire, reveals his newest trading strategy.
Days
Hours
Minutes
Seconds

Palatin Technologies, Inc.
(NYSE Amex Equities : PTN)

( )
PTN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-1.14%78.631.2%$618.81m
AMGNAmgen Inc.
0.16%178.241.2%$557.24m
GILDGilead Sciences, Inc.
-0.22%67.380.9%$542.96m
BIIBBiogen Inc.
0.63%286.211.2%$478.24m
REGNRegeneron Pharmaceuticals, Inc.
-0.30%293.742.6%$304.78m
VRTXVertex Pharmaceuticals Incorporated
0.34%157.501.9%$219.69m
ALXNAlexion Pharmaceuticals, Inc.
0.51%117.742.0%$210.05m
ILMNIllumina, Inc.
-1.70%266.223.5%$198.41m
AAgilent Technologies, Inc.
-1.50%63.161.5%$196.40m
NKTRNektar Therapeutics
-0.77%79.966.0%$184.19m
INCYIncyte Corporation
2.64%68.432.5%$149.75m
BMRNBioMarin Pharmaceutical Inc.
4.77%92.494.4%$135.47m
SRPTSarepta Therapeutics, Inc.
1.85%91.6516.6%$126.22m
BLUEBluebird Bio, Inc.
0.62%188.1515.7%$98.65m
EXASExact Sciences Corporation
-1.95%51.8225.5%$98.64m

Company Profile

Palatin Technologies, Inc. is a biopharmaceutical company which develops targeted, receptor-specific peptide therapeutics for the treatment of diseases. It specializes in molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. It offers product in clinical development is bremelanotide for the treatment of premenopausal women with hypoactive sexual desire disorder, which is a type of female sexual dysfunction, defined as low desire with associated distress. It also offers drug candidates and development programs for cardiovascular diseases and inflammatory diseases. The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.